News

Filter

Current filters:

LucentisFovista

US and European retinal specialists view AMD treatments

US and European retinal specialists view AMD treatments

14-03-2014

Surveyed US and European retinal specialists ascribe a moderate to high unmet need for wet age-related…

BayerEuropeEyleaFovistaLucentisMarkets & MarketingNovartisOphthalmicsOphthotechPharmaceuticalRegeneronRocheUSA

Strong uptake of Regeneron/Bayer wet AMD drug Eylea in USA, but Avastin still leads

11-07-2013

The majority of wet age-related macular degeneration (AMD) patients are administered their first intravitreal…

AllerganAvastinBayerBiotechnologyEyleaFovistaLucentisMarkets & MarketingNorth AmericaOphthalmicsOphthotechPharmaceuticalRegeneronRoche

Ophthotech's Fovista tops Lucentis in wet AMD

15-06-2012

Privately-held US biotech firm Ophthotech Corp has announced results from the first clinical trial to…

BiotechnologyFovistaLucentisOphthalmicsOphthotechResearch

COMPANY SPOTLIGHT

Menarini

Back to top